Sahai, VaibhavRedig, Amanda JCollier, Katharine A.Eckerdt, Frank D.Munshi, Hidayatullah G.2017-03-282016Sahai, Vaibhav, Amanda J. Redig, Katharine A. Collier, Frank D. Eckerdt, and Hidayatullah G. Munshi. 2016. “Targeting BET bromodomain proteins in solid tumors.” Oncotarget 7 (33): 53997-54009. doi:10.18632/oncotarget.9804. http://dx.doi.org/10.18632/oncotarget.9804.http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731792There is increasing interest in inhibitors targeting BET (bromodomain and extra-terminal) proteins because of the association between this family of proteins and cancer progression. BET inhibitors were initially shown to have efficacy in hematologic malignancies; however, a number of studies have now shown that BET inhibitors can also block progression of non-hematologic malignancies. In this Review, we summarize the efficacy of BET inhibitors in select solid tumors; evaluate the role of BET proteins in mediating resistance to current targeted therapies; and consider potential toxicities of BET inhibitors. We also evaluate recently characterized mechanisms of resistance to BET inhibitors; summarize ongoing clinical trials with these inhibitors; and discuss potential future roles of BET inhibitors in patients with solid tumors.en-USNUT midline carcinomabreast and prostate cancerslung cancersgastrointestinal cancersbrain tumorsJournal Article2017-03-2810.18632/oncotarget.9804